Primary Investigator
P. Brandon Bookstaver, Pharm.D.
Associate Professor & Director of Residency and Fellowship Training
University of South Carolina College of Pharmacy
Ready to Participate?
Please complete and submit the Facility Intake / Interest Form.
Overview
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China. Since that time, the World Health Organization has declared a global pandemic with confirmed COVID-19 cases in the millions.
The S.C. Department of Health and Environmental Control is working closely with federal, state, local partners to respond to this ongoing public health event. South Carolinians may be at particularly high risk for COVID-19 due to significant risk factors such as obesity, underlying cardiovascular disease and diabetes mellitus.
Current pharmacologic treatments for COVID-19 are considered experimental and there is significant need for safety and effectiveness data. The S.C. COVID-19 Treatment Outcomes Registry will provide access to that invaluable data for clinicians, regulatory agencies, and scholars across the state.
Co-Primary Investigator
Sharon Weissman, M.D.
Professor of Clinical Internal Medicine
University of South Carolina School of Medicine
Chief of Division of Infectious Diseases
Prisma Health/University of South Carolina Medical Group
Co-Investigators
Divya Ahuja, M.D.
Department of Medicine, Division of Infectious Diseases
University of South Carolina School of Medicine
Prisma Health USC Medical Group
Majdi Al-Hasan, M.D.
Department of Medicine, Division of Infectious Diseases
University of South Carolina School of Medicine
Prisma Health USC Medical Group
Ramesh Bharadwaj, M.D.
Infectious Disease Outpatient Clinic
McLeod Health
Edwin Hayes, M.D.
Department of Medicine, Division of Infectious Diseases
University of South Carolina School of Medicine
Prisma Health USC Medical Group
Julie A. Justo, Pharm.D., M.S.
Department of Clinical Pharmacy & Outcomes Sciences,
University of South Carolina College of Pharmacy
Akin Olatosi, M.D.
HopeHealth
John Schrank, Jr., M.D.
Division of Infectious Diseases, Prisma Health Upstate
Jenna Swindler, Pharm.D.
McLeod Health
Aim 1: Create a statewide registry of hospitalized, COVID-19 infected patients admitted to inpatient facilities in South Carolina
Aim 2: Determine COVID-19 treatment patterns among South Carolina hospitals
Aim 3: Assess short term safety and effectiveness outcomes among the pharmacologic treatment approaches
Aim 4: Assess long term safety and effectiveness outcomes in patients post-discharge
Inclusion Criteria
- COVID-19 positive by polymerase chain reaction (PCR) or equivalent, approved testing method
- Hospitalized in an inpatient facility in South Carolina
- Survived at least 24 hours following admission
- Patients who received at least 1 dose of a pharmacologic therapy intended to treat SARS CoV 2 virus will be evaluated for drug-related adverse event outcomes as discussed below.
Potential treatments include: hydroxychloroquine, chloroquine, tocilizumab, remdesivir, lopinavir/ritonavir, ribavirin, convalescent serum and adjunctive zinc, Vitamin C or azithromycin. Because possible treatments are under investigation, this list is not considered exhaustive.
Exclusion Criteria:
- Patient expired in the initial 24 hours since initial hospital admission (adjusted for facility transfers)
- Pertinent data for registry incomplete due to patient transfer between facilities or limited documentation in electronic health record
 |
|
 |
 |
 |
 |
|
|
This work was supported by the Office of the Vice President for Research at the University of South Carolina .